The Small Animal Cancer Imaging Research Facility (SACIRF) provides cancer investigators with the latest technology and techniques for experimental in vivo imaging of small animals. The facility includes state-ofthe- art instrumentation, including the modalities of magnetic resonance (MR, Bruker4.7 T, 40 cm Biospec), x-ray computed tomography (micro-CT from Enhanced Vision Systems and volume CT being developed in collaboration with General Electric), projection radiography (Faxitron), and nuclear imaging (M.Cam gamma camera from Siemens and micro-PET from Concorde Microsystems). Optical imaging will be added during the first year of the award (instrumentation to be developed in collaboration with Biomedical Engineering at The University of Texas-Austin). This instrumentation represents a >$3M investment by MDACC. The SACIRF has allocated space for the instruments in the animal support facilities to facilitate the inclusion of the imaging studies in ongoing cancer research, and dedicated office and developmental laboratory space to support the facility operation. The faculty and staff are well-qualified in each of the modality areas, including current image acquisition and image analysis techniques. Specialty areas include quantitative tissue characterization (MR), imaging of microvascular physiology (MR, nuclear, CT and optical), diffusion imaging for estimating cellular density (MR), metabolic imaging (nuclear, positron emission tomography [PET], optical and MR spectroscopy), and vascular imaging (MR, CT, and x-ray). The services of the facility include imaging protocol design, custom positioning systems, custom data acquisition hardware and software, image analysis, data archiving, provision of hardcopy and digital data delivery, and database maintenance. The Veterinary Core includes a dedicated support team that provides highly efficient imaging studies and a very low mortality rate of animals during the imaging procedures. Services provided from the Veterinary Core include development of veterinary support protocols specific to each experimental design, and consultation on the inclusion of imaging procedures into existing protocols to obtain Institutional Animal Care and Use Committee approval. To date, 75 investigators representing 13 programs have used facility instrumentation. 42% of the users are peer-review-funded investigators. Utilization continues to increase as the facility and its capabilities become better known to the local cancer research community. The capabilities of the facility continue to grow to meet experimental demands. Publications are evolving at a rapid pace, and although only a few are published, the acceptance rate has been nearly 100%. Funding for the SACIRF is currently CCSG (43%), user fees (36%), and MDACC (21%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$236,872
Indirect Cost
$83,063
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications